- Home
- HRMY vs IRON Comparison
HRMY vs IRON Comparison
Compare HRMY & IRON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- IRON
- Stock Information
- Founded
- HRMY 2017
- IRON 2017
- Country
- HRMY United States
- IRON United States
- Employees
- HRMY N/A
- IRON N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- IRON Biotechnology: Pharmaceutical Preparations
- Sector
- HRMY Health Care
- IRON Health Care
- Exchange
- HRMY Nasdaq
- IRON Nasdaq
- Market Cap
- HRMY 1.8B
- IRON 2.1B
- IPO Year
- HRMY 2020
- IRON N/A
- Fundamental
- Price
- HRMY $34.94
- IRON $60.83
- Analyst Decision
- HRMY Strong Buy
- IRON Strong Buy
- Analyst Count
- HRMY 9
- IRON 12
- Target Price
- HRMY $55.33
- IRON $92.08
- AVG Volume (30 Days)
- HRMY 627.0K
- IRON 354.0K
- Earning Date
- HRMY 08-05-2025
- IRON 08-15-2025
- Dividend Yield
- HRMY N/A
- IRON N/A
- EPS Growth
- HRMY 58.41
- IRON N/A
- EPS
- HRMY 3.10
- IRON N/A
- Revenue
- HRMY $772,527,000.00
- IRON N/A
- Revenue This Year
- HRMY $20.45
- IRON N/A
- Revenue Next Year
- HRMY $17.32
- IRON N/A
- P/E Ratio
- HRMY $11.29
- IRON N/A
- Revenue Growth
- HRMY 17.74
- IRON N/A
- 52 Week Low
- HRMY $26.47
- IRON $30.82
- 52 Week High
- HRMY $41.61
- IRON $68.73
- Technical
- Relative Strength Index (RSI)
- HRMY 50.27
- IRON 63.86
- Support Level
- HRMY $34.09
- IRON $58.01
- Resistance Level
- HRMY $36.09
- IRON $61.59
- Average True Range (ATR)
- HRMY 1.42
- IRON 2.12
- MACD
- HRMY -0.19
- IRON -0.20
- Stochastic Oscillator
- HRMY 46.42
- IRON 74.68
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About IRON Disc Medicine Inc.
Disc Medicine Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for hematologic diseases. It aims to modify fundamental biological pathways associated with the formation and function of red blood cells, specifically heme biosynthesis and iron homeostasis. Its pipeline includes bitopertin for erythropoietic porphyrias (EPs) including erythropoietic protoporphyria (EPP), X-linked protoporphyria (XLP), and Diamond-Blackfan Anemia (DBA); DISC-0974 for the treatment of anemia of myelofibrosis (MF) and anemia of chronic kidney disease (CKD); and DISC-3405 for the treatment of polycythemia vera (PV) and other hematologic disorders. In addition, the Company's preclinical programs include DISC-0998.